 0, 3, 6, 12 were 7.23, 8.59, 8.35, 8.60 
Introduction

The prognosis of HIV-1 patients has been remarkably improved by highly active antiretroviral therapies (HAART). However, many patients have suffered from long-term adverse effects including lipoatrophy, which markedly interferes with their quality of life (1, 2). Recombinant human growth hormone (rhGH) has been used for patients with fat redistribution syndrome and has shown favorable outcomes in trunk, limbs or lipid profile
. Among this syndrome, a significant percentage of patients has experienced facial lipoatrophy, which has one of the strongest impacts on their quality of life (6, 7) . This prospective study was undertaken to focus on the effect of subcutaneous growth hormone in HIV-1 patients with moderate to severe facial lipoatrophy. T a b l e 1 . F a c i a l L i p o a t r o p h y S e v e r i t y S c a l e T a b l e 2 . Ch a r a c t e r i s t i c s o f P a t i e n t s a t E n t r y 3) (Fig. 1 
Method Patients
). Dunnett-Hsu analysis of adjusted multiple comparison of least squares means found significant improvement of soft tissue thickness from the baseline in the month 3 (p=0.009) and month 12 (p= 0.021). Even after the completion of rhGH injection at month 6, the soft tissue at the level of zygomatics showed no significant decrease for the follow-up period.
There was no significant change in the circumference of arm and thigh, and liver function, CD4 nor HIV viral load during the study. BMI and lipid profile also showed no change except for glucose between months 0 and 6, both of which were within the normal limit (Table 3) . T a b l e 3 . Ch a n g e o f L a b o r a t o r y Ch a r a c t e r i s t i c 
F i g u r e 1 . T h i c k n e s s o f b i l a t e r a l s o f t t i s s u e a t t h e l e v e l o f z y g o ma t i c s , 9 5 %CI s .
Discussion
Facial lipoatrophy is one of the long-term adverse effects of HAART for which standard treatment is not yet found and it severely interferes with the patient's quality of life.
Several studies using surgical intervention have been reported to show limited transient effects (8) . Some studies have reported the effect of growth hormone for lipoatrophy or lipodystrophy in relation to the total body composition or glucose metabolism (3-6, 11, 12 
